US20010007866A1 - Treatment of pruritus with vitamin d and analogs thereof - Google Patents

Treatment of pruritus with vitamin d and analogs thereof Download PDF

Info

Publication number
US20010007866A1
US20010007866A1 US09/123,885 US12388598A US2001007866A1 US 20010007866 A1 US20010007866 A1 US 20010007866A1 US 12388598 A US12388598 A US 12388598A US 2001007866 A1 US2001007866 A1 US 2001007866A1
Authority
US
United States
Prior art keywords
vitamin
pruritus
therapeutically effective
analog
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/123,885
Inventor
Marilyn E. Strube
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US09/123,885 priority Critical patent/US20010007866A1/en
Publication of US20010007866A1 publication Critical patent/US20010007866A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Definitions

  • This invention relates generally to the field of treating pruritus and, more particularly, to the topical treatment of pruritus using vitamin D and analogs thereof.
  • Pruritus is a condition involving localized or general itching which can be mediated by stimulation of sensory nerve endings. Although usually occurring in the skin, pruritus can also occur in non-cutaneous sites such as mucous membranes or cornea. A variety of causes for the condition of pruritus are known including external and exogenous causes, localized skin disorders and systemic diseases.
  • the first line of treatment involves diagnosis of the underlying condition that causes the pruritus and intervening therapeutically to alleviate that underlying condition.
  • Such therapeutic treatment is appropriate for example in the treatment of psoriasis with UV light or with topical vitamin D 3 analogs.
  • These treatments are not considered to be direct treatments of the pruritus and only indirectly relieve the itching. Indeed, some treatment modalities for psoriasis can cause itching (for example, see product insert for the vitamin D analog Dovonex®, Westwood-Squibb).
  • the underlying disease it might also be desirable to directly treat the pruritus.
  • either the underlying cause for the pruritic condition cannot be determined or it cannot be eliminated. In such cases the direct treatment of the pruritic condition is required.
  • Nonspecific topical preparations can act as moisturizing lotions or creams or as oil-based ointments that are occlusive and serve to soften dry skin as well as providing a protective covering. These can sometimes contain chemical substances in the preparation which do not contribute to the nonspecific antipruritic action of the preparation and provide no antipruritic action themselves.
  • Topical formulations containing pharmacologically active agents are often useful in particular pruritic conditions but may not be generally useful in all pruritic conditions.
  • topical corticosteroids are not indicated for symptomatic treatment unless a steroid responsive disorder is diagnosed.
  • Physical modalities such as UV light have been particularly effective in a variety of conditions although undesirable side effects can be produced by UV light such as an increased risk of developing skin cancer as well as undesirable phototoxic reactions (see for example, Marks, J Dermatol Treat 1:233-234, 1989)
  • Vitamin D 3 is also incidentally present in some formulations that are indicated to be useful in certain conditions involving itching.
  • One such nonspecific topical preparation was reported In U.S. Pat. No. 3,711,602 issued to Herschler. This patent discloses a formulation containing lanolin, DMSO, isopropyl myristate, vitamin A and vitamin D 3 that is applied topically for the treatment of burns, skin irritation, diaper rash and pruritus. This preparation is nonaqueous and provides occlusion and physical soothing actions. It is believed, however, that the vitamin D present in the formulation at a concentration of 7.5 ⁇ g/ml does not directly contribute any anti-pruritic effect. This is because the lowest concentration found to have an anti-pruritic effect in a non-aqueous vehicle in the studies reported herein was 521 ⁇ g/ml.
  • vitamin D such as for example A and D® Ointment for soothing relief of diaper rash or Desitin® also used to sooth diaper rash including preventing the burning, pain and itch produced by irritants.
  • preparations provide only a protective physical barrier to water and irritants and the vitamin D present in these preparations is incapable of producing any direct antipruritic action as a result of not being bioavailable from such formulations.
  • vitamin D 3 has been incidentally related to some treatment modalities for pruritus, it has not heretofore been known that vitamin D 3 can be effectively used in the treatment of pruritic conditions.
  • vitamin D can be applied topically in certain formulations that make the vitamin D bioavailable. Surprisingly, when administered in such formulations at pruritic sites, the vitamin D becomes therapeutically effective and the pruritus is rapidly and completely relieved.
  • vitamin D is a fat soluble substance
  • a water-based emulsion formulation that is bioavailable and suitable for topical treatment can be used.
  • one formulation for vitamin D that is effective in-treating pruritus comprises a mixture of water, a water-insoluble organic liquid, a surface active agent, and a vitamin D or an analog thereof. This formulation is effective when the vitamin D is present at a concentration as low as 2.5 ⁇ g/ml.
  • a second formulation that is also effective in treating pruritus is based upon a nonaqueous carrier vehicle for vitamin D.
  • This formulation comprises a water-insoluble organic liquid such as petroleum or corn oil and vitamin D.
  • the vitamin D concentration in this formulation can be as low as 521 ⁇ g/ml.
  • vitamin D formulation effective in treating pruritus comprises a suspension of water and a dispersed phase containing vitamin D or analog thereof. This formulation is effective at concentration of 12.5 ⁇ g/ml.
  • FIGURE illustrates the concentration-response relationship of the antipruritic effect of vitamin D 3 (0.25-5.0 ⁇ g/ml) in alleviating the itching produced by poison ivy.
  • the present invention is thus based upon the discovery that vitamin D can effectively treat pruritic conditions when administered topically in a therapeutically effective formulation.
  • a therapeutically effective formulation it is meant that the active substance is bioavailable, that is able to exert a biological activity when administered in that formulation.
  • Such formulations effectively exhibit the biological activity of vitamin D in diminishing or completely alleviating the itching involved in pruritic conditions.
  • the formulation is also pharmaceutically acceptable for topical application.
  • Vitamin D within the scope of this invention is intended to include vitamin D 3 or cholecalciferol as well as the several related steroids and their metabolites that are referenced in the art by the term vitamin D provided such compound show the biological activity of vitamin D.
  • vitamin D compounds include alfacalcidol, calcifedol, calcitriol, cholecalciferol, dihydrotachysterol, and ergocalciferol (Martindale, The Extra Pharmacopoeia 30 th Ed., Martindale, 1993, pp. 1058-1059).
  • vitamin D Also included within the scope of this invention and within the meaning of the term vitamin D are analogs of vitamin D. Analogs of vitamin D are well known in the art and such compounds can have modifications in the side chain and/or changes in the nuclear part of the secosteroid molecule. Vitamin D analogs can contain side chain modifications involving introduction of unsaturation; transposing, adding, removing or substituting hydroxyl groups; substituting hydrogens; forming carbocyclic structure; introducing a heteroatom link; inverting stereochemically; removing or adding alkyl groups and changing the number of links in the side chain.
  • vitamin D so long as they exhibit the biological activity of antipruritic effectiveness in a bioavailable formulation.
  • Such biologically active vitamin D compounds may not show the same degree of activity as vitamin D 3 , but need only show at least some discernable antipruritic effect.
  • One embodiment of the present invention is an aqueous-based emulsion formulation comprising water, a water-insoluble organic liquid, a surface active agent and vitamin D.
  • the surface active agent is biocompatible and suitable for application by topical formulation.
  • the formulation also contains a biocompatible water-insoluble organic liquid such as an oil or lipid suitable for forming an oil-in-water or water-in-oil emulsion so that the formulation is a cream, ointment, paste or the like.
  • biocompatible it is meant that the substance produces no untoward biological effects such as local or generalized toxic effects or local irritation at the site of topical application.
  • Suitable water-insoluble organic liquids are well known in the art field of topically applied cosmetics and therapeutics and include but are not limited to mineral oil, corn oil or other vegetable oil, petroleum, lanolin, fish oil and the like.
  • biocompatible surface active agents can be used in the present invention including but not limited to (1) anionic surfactants such as monovalent or polyvalent carboxylate salts, acyl lactylates, alkyl ether carboxylates, N-Acyl Sarcosinates, N-Acyl Glutamates, fatty acid-polypeptide condensates, sulfuric acid esters including alkyl sulfates and ethoxylated alkyl sulfates, ester-linked sulfonates, alpha olefin sulfonates, phosphated ethoxylated alcohols; (2) cationic surfactants such as monoalkyl quaternary ammonium salts, dialkyl quaternary ammonium compounds, amidoamines and aminimides; (3) amphoteric surfactants such as N-substituted alkyl amides, N-alkyl betaines, sulfobetaines, and N-al
  • the selection of a particular surface active agent would depend upon a number of factors including but not limited to the particular causation agent for the pruritic condition and whether topical lesions accompany the pruritic condition.
  • the formulations of the present invention are useful in treating pruritic conditions on the skin, mucous membranes or cornea. Selection of a suitable surface active agent can thus be based in part on the site being treated. For example, amphoteric or nonionic surface active agents known in the art are selected for uses in and around the eyes to avoid corneal irritation.
  • One skilled in the art can readily select a surface active agent and formulation suitable for a particular site and pruritic condition as well as for other factors.
  • a water-insoluble formulation comprising a biocompatible, water-insoluble organic liquid such as a biocompatible oil or lipid suitable as a carrier for the vitamin D.
  • a biocompatible, water-insoluble organic liquid such as a biocompatible oil or lipid suitable as a carrier for the vitamin D.
  • the carrier must be suitable in the sense of being compatible with the vitamin D and any other ingredients and not deleterious to the patient being treated.
  • Suitable organic liquids include petroleum jelly, corn oil or other vegetable oil, mineral oil, lanolin, fish oil and the like.
  • the Vitamin D compounds of the present invention can also be formulated into bioavailable suspensions or dispersions such as, for example, hydrosols and hydrogels in which a true emulsion is not formed.
  • the formulation is a mixture of two or more substances forming a dispersed phase which is finely divided and uniformly distributed through a dispersion medium which is usually water.
  • the dispersed phase can be a solid or an oil phase with stabilizers to form a stabilized colloidal system.
  • Suspending or dispersing agents may also be added to the formulation and can include surface active agents capable of stabilizing the suspension or dispersion.
  • the preparation of suspensions and ingredients used in the formation of suspensions are well known in the art and one skilled in the art can readily prepare such suspension.
  • the formulations of this invention may also include one or more additional auxiliary ingredients such as diluents, buffers, or preservatives such as methyl hydroxybenzoate and/or anti-oxidants and the like.
  • additional ingredients can also be pharmaceutically-acceptable excipients for modifying or maintaining the pH, osmolarity, viscosity, clarity, color, sterility, stability, rate of dissolution, or odor of the formulation.
  • the formulation may contain still other pharmaceutically-acceptable excipients for modifying or maintaining release or absorption or penetration of the site by the vitamin D compound.
  • other therapeutic substances can be incorporated into the formulation such as, for example, other antipruritic agents, vitamins, antifungals, antiinflammatory agents, antibiotics, sunscreens and the like.
  • the topical formulations described herein can be used in treating virtually any pruritic site such as for example on the skin, mucous membranes or cornea.
  • Such treatments include scalp treatment as in shampoos, conditioners and the like, rectal treatment, eye treatment, treatment of nasal membranes, treatment of the ear canal, etc.
  • the formulations in the present invention are intended for use in treating a wide variety of pruritic conditions in humans as well as in non-human mammals, birds, reptiles, amphibians and fish.
  • Conditions that are intended for treatment by the present invention include but are not limited to chickenpox, shingles, plant toxins such as poison ivy, insect bites, chronic kidney failure, liver diseases such as primary biliary cirrhosis and alcoholic cirrhosis, malabsorption syndromes such as steatorhea, HIV infection, AIDS related eosinophilic pustular folliculitus, psoriasis, atopic dermatitis, photosensitivity disorders, lichen planus, polycythemia vera, Grover's disease, glanuloma annulare, lichen nitidus, prurigo nodularis, macular amyloidosis, urticaria pigmentosa, aquagenic pruritus, pemphigus vulgarus, lupis vulgaris,
  • This example illustrates antipruritic effect of vitamin D 3 in Vita Moist Hand and Nail Cream in the alleviating the pruritus of chickenpox.
  • Vita Moist Hand and Nail Cream hereinafter referenced as Vita Moist Cream and the pruritus was completely and immediately alleviated.
  • the effect of the cream lasted for several hours and when the itching returned, I reapplied the cream with the result that the pruritus was again completely and immediately alleviated.
  • Vita Moist Cream is sold as a skin moisturizer and carries no indication for use in treating pruritus. Upon reviewing the medical literature, I learned that UVB light was effective in treating pruritic conditions and that, incidentally, UVB light also produces vitamin D 3 , I concluded that vitamin D 3 was likely to be the active ingredient in Vita Moist Cream. As commercially available, Vita Moist Cream contains 10 ⁇ g/ml vitamin D 3 among other ingredients.
  • Vita Moist Cream Ingredients present in Vita Moist Cream are as follows: VITA MOIST CREAM A Purified Water E Glycol Stearate E Glycerin E Isopropyl Palmitate E Dimethicone E Myristyl Myristate E Peg-40 Stearate E Stearyl Alcohol E Steareth-2 E Mineral Oil F Methylparaben F Imidazolidinyl Urea F Triethanolamine F Fragrance F Carbomer-934 .02000 Retinyl Palmitate .02000 Tocopheryl Acetate G Corn Oil G Hydrolyzed Animal Keratin G Propylene Glycol G SD Alcohol 40-B .00100 Cholecalciferol G Disodium EDTA G FD&C Yellow No. 5 G FD&C Red No. 4 G EXT D&C Violet No. 2
  • This example illustrates the antipruritic effect of vitamin D 3 formulated in corn oil for alleviating the pruritus of sunburn.
  • a corn oil solution of vitamin D 3 was prepared by adding 1 gram of vitamin D 3 to 20 ml corn oil with mixing for approximately 1 hour followed by brief heating to approximately 45° C. until dissolved. One ml of this solution was mixed with 47 ml corn oil and 2 ml isopropyl myristate to obtain a final concentration of vitamin D 3 of 1000 ⁇ g/ml.
  • This example illustrates the antipruritic effect of vitamin D 3 formulated in water-based emulsions in alleviating the pruritus caused by poison ivy.
  • Water-based emulsions were prepared using Keri® lotion (Bristol-Meyers Squibb Co., N.Y.) and Eucerin® lotion (Beiersdorf, Inc., Norwalk, Conn.).
  • Keri® lotion has the following composition as indicated on the container label.
  • Eucerin® lotion has the following composition as indicated on the container label.
  • Keri® lotion preparations were made containing various concentrations of vitamin D 3 by mixing stock solutions as indicated below and heating the mixture at 46-50° C. with occasional stirring. 869 ⁇ g/ml: One ml of the 5% solution of vitamin D 3 from example 2 was mixed with 2 ml corn oil to obtain 16,666 ⁇ g/ml solution. 0.55 ml of this solution was then mixed with ten ml of Keri® lotion. 521 ⁇ g/ml: 0.55 ml of vitamin D 3 in corn oil at 10,000 ⁇ g/ml as described above was added to 10 ml Keri® Lotion.
  • 502 ⁇ g/ml 0.55 ml of the 10,000 solution of was mixed with 10 ml Keri® Lotion and 0.4 ml isopropyl myristate.
  • 52 ⁇ g/ml 0.55 ml of 1,000 ⁇ g/ml stock solution, prepared by mixing 1 ml of 5% vitamin D 3 stock with 2 ml isopropyl myristate and 47 ml corn oil, was added to 10 ml Keri® Lotion.
  • Eucerin® lotion preparation at 869 ⁇ g/ml was made as described above for Keri® lotion.
  • Vita Moist Cream had the composition as shown in example 1.
  • Testing Procedure Subject MS contracted poison ivy rash and tested the various preparations above. Preparations were evaluated by the subject after application to an area of rash approximately 1-10 square centimeters. Comparisons were made of antipruritic effect by marking on a 100 mm visual analog scale consisting of a plain line with the left end labeled “None” and the right end labeled “Maximal”. The subject was instructed to mark the scale at a point which she felt corresponded to the level of itchiness that she was feeling at the treatment site at the appropriate time. The samples were coded so that the subject was not aware of what a given sample was and she was not told if they were expected to have an effect.
  • Table 1a shows an antipruritic effect of Vita Moist Cream containing vitamin D 3 at 10 ⁇ g/ml compared to the control cream, Care Deeply. The pruritus was completely alleviated one minute after application.
  • VITA MOIST Vitamin D 3 - 10 ⁇ g/ml* Time Care Deeply Vita Moist (min) Control (D 3 - 10 ⁇ g/ml) 0 81 81 1 75 0 5 74 0 10 76 0
  • Table 1c shows that concentrations of vitamin D 3 from 10 through 869 ⁇ g/ml are effective in rapidly and effectively relieving pruritus.
  • Table 1c KERI LOTION (with added Isopropyl Myristate) Time Vitamin D 3 Concentrations (min) 0 10** 52 502 521* 869 0 82 79 77 80 80 82 1 66 0 35 0 81 0 5 47 0 0 0 0 0 10 25 0 0 0 0 0 0 0 0 0 0
  • This example illustrates the antipruritic effect of vitamin D 3 formulated in oil-based preparations in alleviating the pruritus caused by poison ivy.
  • a petroleum jelly formulation was prepared as follows. One gram of vitamin D 3 was dissolved in 20 ml corn oil as described in example 2. One ml of the resultant 5% solution was mixed with 4 ml corn oil to obtain a 10,000 ⁇ g/ml solution. Ten ml of petroleum jelly was then mixed with 0.55 ml of the 10,000 ⁇ g/ml solution upon heating to 50-55° C. to give a resultant concentration of 521 ⁇ g/ml. Placebo control was made by adding 0.55 ml corn oil to 10 ml petroleum jelly.
  • the corn oil formulation was prepared by adding 1 ml of the 5% stock solution of vitamin D 3 in 2 ml isopropyl myristate and 47 ml corn oil to give a final concentration of 1000 ⁇ g/ml.
  • Vitamin A and D Ointment contained the label-indicated ingredients of vitamin A at 1856 I.U./g and vitamin D at 270 I.U./g or 6.75 ⁇ g/ml in white petrolatum and zinc oxide.
  • This example illustrates the antipruritic effect of vitamin D 3 formulated in a water-based suspension in alleviating the pruritus caused by poison ivy.
  • Vita Moist Cream was used as control reference formulation and this had the composition as shown in example 1.
  • Vita Moist Body Lotion (Avon, N.Y.), is a commercially available aqueous suspension formulation containing vitamin D 3 . This composition contains the following ingredients.
  • Vita Moist Cream again completely alleviated the pruritus, although in this test, complete effectiveness was seen at the 5 minute observation rather than at the 1 minute observation in example 3. In comparison to this, Vita Moist Lotion only partially alleviation of the pruritis at 5 minutes and nearly complete relief was obtained by 10 minutes. Thus the suspension preparation appeared to be less rapid in producing the antipruritic effect than was the emulsion preparation, Vita Moist Cream.
  • This example illustrates the dose-response relationship of Vitamin D 3 in a water-based emulsion vehicle prepared by mixing Vita Moist Cream containing Vitamin D 3 with Care Deeply Cream which contains no Vitamin D 3 .
  • vitamin D formulations will be tested against placebo.
  • the vitamin D preparations will be based upon the formulations discussed above.
  • the placebo will contain only the formulation without vitamin D.
  • the study would be double blind, meaning that both the nurse and the patient will be unaware of which cream contains the test material and which contains only placebo.
  • the containers will be coded so that only the attending physician will know which is which. The code may be different from one formulation set to the next.
  • the nurse protecol is as follows:
  • the patient must be suffering from chronic kidney failure and be experiencing bothersome itchiness at the time of the office visit. The patient will be asked if they would like to volunteer to try this new treatment. It will be explained that this is a trial of a cream that relieves itchiness in chickenpox and poison ivy and that it may or may not help them.
  • the patient will be assisted in understanding and completing the questionnaire. If needed, the nurse can assist by writing the answers given by the patient.
  • the questionnaire is as follows: Cream Number — — 1. Patient's name and phone number. 2. Date and time. 3. Age/Sex. 4. Date when dialysis was started. 5. What kind of renal disease do you have? 6. Do you have a history of persistent itchiness? If so, for how long? 7. Is your itchiness constant or does it come and go? If it's not constant, when is it usually the worst? 8. Are you itching right now? 9. Do you have itchiness all over your body or only on part of your body? If only on part of your body, please indicate where. 10. What treatments have you tried to reduce the itchiness and which have been the most effective? Nurses' comments (to be filled out after evaluation): Follow up comments: Nurses' signature Doctors' signature
  • Treatment is evaluated by the patient as discussed in Example 3 above.
  • the patient is instructed as to how to mark the 100 mm visual scale from “None” to “Maximal” pruritus.
  • the scale is explained with no suggestion as to where the mark should be placed. Only the patient will decide where to place the mark.
  • Patient's name and date: TREATMENT EVALUATION Please indicate how serious the itchiness is using the following scales. make a mark on the line at the point that you feel corresponds to the severity of the itchiness that you are experiencing at the treatment sites for each appropriate time. Slight itchiness would be indicated by making a mark near the left side of the scale while severe itchiness would be indicated by making a mark near the right side of the scale.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A method for treating pruritus comprising topical administration of formulation of vitamin D or an analog of vitamin D is disclosed. The formulation comprises a therapeutically effective, water-based emulsion, water-based suspension or oil-based formulation of vitamin D or analog of vitamin D.

Description

    BACKGROUND OF THE INVENTION
  • (1) Field of the Invention [0001]
  • This invention relates generally to the field of treating pruritus and, more particularly, to the topical treatment of pruritus using vitamin D and analogs thereof. [0002]
  • (2) Description of the Related Art [0003]
  • Pruritus is a condition involving localized or general itching which can be mediated by stimulation of sensory nerve endings. Although usually occurring in the skin, pruritus can also occur in non-cutaneous sites such as mucous membranes or cornea. A variety of causes for the condition of pruritus are known including external and exogenous causes, localized skin disorders and systemic diseases. [0004]
  • The first line of treatment involves diagnosis of the underlying condition that causes the pruritus and intervening therapeutically to alleviate that underlying condition. Such therapeutic treatment is appropriate for example in the treatment of psoriasis with UV light or with topical vitamin D[0005] 3 analogs. These treatments are not considered to be direct treatments of the pruritus and only indirectly relieve the itching. Indeed, some treatment modalities for psoriasis can cause itching (for example, see product insert for the vitamin D analog Dovonex®, Westwood-Squibb). At the same time the underlying disease is being treated, it might also be desirable to directly treat the pruritus. Furthermore in some conditions involving pruritus, either the underlying cause for the pruritic condition cannot be determined or it cannot be eliminated. In such cases the direct treatment of the pruritic condition is required.
  • Currently available treatment modalities for pruritus include nonspecific topical agents such as emollients and counterirritants, topical drugs such as steroids, local anesthetics and antihistamines, and physical modalities such as ultraviolet phototherapy and thermal stimulation. Some of these treatments are effective in pruritic conditions of particular etiology, while others may show general but nonspecific benefit. [0006]
  • Nonspecific topical preparations can act as moisturizing lotions or creams or as oil-based ointments that are occlusive and serve to soften dry skin as well as providing a protective covering. These can sometimes contain chemical substances in the preparation which do not contribute to the nonspecific antipruritic action of the preparation and provide no antipruritic action themselves. [0007]
  • Topical formulations containing pharmacologically active agents are often useful in particular pruritic conditions but may not be generally useful in all pruritic conditions. For example, topical corticosteroids are not indicated for symptomatic treatment unless a steroid responsive disorder is diagnosed. Physical modalities such as UV light have been particularly effective in a variety of conditions although undesirable side effects can be produced by UV light such as an increased risk of developing skin cancer as well as undesirable phototoxic reactions (see for example, Marks, [0008] J Dermatol Treat 1:233-234, 1989) Thus it would be desirable to develop new anti-pruritic agents that are effective in treating pruritus resulting from a wide variety of causes or that are able to alleviate pruritus produced by different causes than those that can be treated by currently available agents.
  • The ability of vitamin D[0009] 3 to effectively treat pruritus when administered in a topical treatment formulation has not been heretofore known. The effectiveness of UVB light therapy in the treatment of pruritus has been noted to be incidentally related to the production of vitamin D in the skin (Blachley et al., Am J Kidney Dis 5:237-241, 1985). The same wavelengths of between 290 and 310 nm used in UVB treatment is also able to photolyze provitamin D3(7-dehydrocholesterol) which then internally isomerizes to form vitamin D3. Nevertheless no direct link between vitamin D3 production in the skin and the antipruritic effectiveness of UVB light treatment has been reported and, in addition, the mechanism of the therapeutic benefit of UVB light remains unknown.
  • Vitamin D[0010] 3 is also incidentally present in some formulations that are indicated to be useful in certain conditions involving itching. One such nonspecific topical preparation was reported In U.S. Pat. No. 3,711,602 issued to Herschler. This patent discloses a formulation containing lanolin, DMSO, isopropyl myristate, vitamin A and vitamin D 3 that is applied topically for the treatment of burns, skin irritation, diaper rash and pruritus. This preparation is nonaqueous and provides occlusion and physical soothing actions. It is believed, however, that the vitamin D present in the formulation at a concentration of 7.5 μg/ml does not directly contribute any anti-pruritic effect. This is because the lowest concentration found to have an anti-pruritic effect in a non-aqueous vehicle in the studies reported herein was 521 μg/ml.
  • Other preparations that serve as nonspecific, physically soothing formulations also sometimes contain vitamin D such as for example A and D® Ointment for soothing relief of diaper rash or Desitin® also used to sooth diaper rash including preventing the burning, pain and itch produced by irritants. These preparations, however, provide only a protective physical barrier to water and irritants and the vitamin D present in these preparations is incapable of producing any direct antipruritic action as a result of not being bioavailable from such formulations. [0011]
  • Thus, although vitamin D[0012] 3 has been incidentally related to some treatment modalities for pruritus, it has not heretofore been known that vitamin D3 can be effectively used in the treatment of pruritic conditions.
    • SUMMARY OF THE INVENTION
  • In accordance with the present invention, it has been discovered that vitamin D can be applied topically in certain formulations that make the vitamin D bioavailable. Surprisingly, when administered in such formulations at pruritic sites, the vitamin D becomes therapeutically effective and the pruritus is rapidly and completely relieved. [0013]
  • Because vitamin D is a fat soluble substance, a water-based emulsion formulation that is bioavailable and suitable for topical treatment can be used. Thus, one formulation for vitamin D that is effective in-treating pruritus comprises a mixture of water, a water-insoluble organic liquid, a surface active agent, and a vitamin D or an analog thereof. This formulation is effective when the vitamin D is present at a concentration as low as 2.5 μg/ml. [0014]
  • A second formulation that is also effective in treating pruritus is based upon a nonaqueous carrier vehicle for vitamin D. This formulation comprises a water-insoluble organic liquid such as petroleum or corn oil and vitamin D. The vitamin D concentration in this formulation can be as low as 521 μg/ml. [0015]
  • Another vitamin D formulation effective in treating pruritus comprises a suspension of water and a dispersed phase containing vitamin D or analog thereof. This formulation is effective at concentration of 12.5 μg/ml. [0016]
  • Among the several advantages achieved by the present invention, therefore, may be noted the provision of new treatment for pruritus that is broadly effective in a variety of pruritic conditions; the provision of a treatment modality that is safe being neither irritating nor toxic; the provision of a treatment that is inexpensive; and the provision of a treatment that has a low potential for sensitizing the treatment site by virtue of its being an endogenous or closely related to an endogenous substance. [0017]
    • BRIEF DESCRIPTION OF THE DRAWING
  • The FIGURE illustrates the concentration-response relationship of the antipruritic effect of vitamin D[0018] 3 (0.25-5.0 μg/ml) in alleviating the itching produced by poison ivy.
    • DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • The present invention is thus based upon the discovery that vitamin D can effectively treat pruritic conditions when administered topically in a therapeutically effective formulation. By a therapeutically effective formulation it is meant that the active substance is bioavailable, that is able to exert a biological activity when administered in that formulation. Such formulations effectively exhibit the biological activity of vitamin D in diminishing or completely alleviating the itching involved in pruritic conditions. The formulation is also pharmaceutically acceptable for topical application. [0019]
  • Vitamin D within the scope of this invention is intended to include vitamin D[0020] 3 or cholecalciferol as well as the several related steroids and their metabolites that are referenced in the art by the term vitamin D provided such compound show the biological activity of vitamin D. Thus vitamin D compounds include alfacalcidol, calcifedol, calcitriol, cholecalciferol, dihydrotachysterol, and ergocalciferol (Martindale, The Extra Pharmacopoeia 30th Ed., Martindale, 1993, pp. 1058-1059).
  • Also included within the scope of this invention and within the meaning of the term vitamin D are analogs of vitamin D. Analogs of vitamin D are well known in the art and such compounds can have modifications in the side chain and/or changes in the nuclear part of the secosteroid molecule. Vitamin D analogs can contain side chain modifications involving introduction of unsaturation; transposing, adding, removing or substituting hydroxyl groups; substituting hydrogens; forming carbocyclic structure; introducing a heteroatom link; inverting stereochemically; removing or adding alkyl groups and changing the number of links in the side chain. (see Calverly and Jones, in [0021] Antitumor Steroids blickenstagg, Ed., Academic Press, Inc., San Diego, 1992, 193-270 which is incorporated by reference). All of these compound are thus included in the term vitamin D so long as they exhibit the biological activity of antipruritic effectiveness in a bioavailable formulation. Such biologically active vitamin D compounds may not show the same degree of activity as vitamin D3, but need only show at least some discernable antipruritic effect.
  • One embodiment of the present invention is an aqueous-based emulsion formulation comprising water, a water-insoluble organic liquid, a surface active agent and vitamin D. The surface active agent is biocompatible and suitable for application by topical formulation. The formulation also contains a biocompatible water-insoluble organic liquid such as an oil or lipid suitable for forming an oil-in-water or water-in-oil emulsion so that the formulation is a cream, ointment, paste or the like. By biocompatible it is meant that the substance produces no untoward biological effects such as local or generalized toxic effects or local irritation at the site of topical application. Suitable water-insoluble organic liquids are well known in the art field of topically applied cosmetics and therapeutics and include but are not limited to mineral oil, corn oil or other vegetable oil, petroleum, lanolin, fish oil and the like. [0022]
  • The use of surface active agents in preparations that are topically applied is well known particularly in the field of cosmetics (for example see [0023] Surfactants in Cosmetics, Rieger, M., Ed., Marcel Dekker, Inc., N.Y., 1985 which is incorporated by reference). Thus, a number of biocompatible surface active agents can be used in the present invention including but not limited to (1) anionic surfactants such as monovalent or polyvalent carboxylate salts, acyl lactylates, alkyl ether carboxylates, N-Acyl Sarcosinates, N-Acyl Glutamates, fatty acid-polypeptide condensates, sulfuric acid esters including alkyl sulfates and ethoxylated alkyl sulfates, ester-linked sulfonates, alpha olefin sulfonates, phosphated ethoxylated alcohols; (2) cationic surfactants such as monoalkyl quaternary ammonium salts, dialkyl quaternary ammonium compounds, amidoamines and aminimides; (3) amphoteric surfactants such as N-substituted alkyl amides, N-alkyl betaines, sulfobetaines, and N-alkyl beta-aminopropionates; and (4) nonionic surfactants such as (a) polyoxyethylene compounds including ethoxylated alcohols, ethoxylated esters and ethoxylated amines; (b) polyoxypropylene compounds such as propoxylated alcohols, ethoxylated/propoxylated block polymers and propoxylated esters; (c) alkanolamines; (d) amine oxides; and (e) fatty acid esters of polyhydric alcohols such as ethylene glycol esters, diethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl fatty acid esters, sorbitan esters, sucrose esters and glucose esters.
  • The selection of a particular surface active agent would depend upon a number of factors including but not limited to the particular causation agent for the pruritic condition and whether topical lesions accompany the pruritic condition. The formulations of the present invention are useful in treating pruritic conditions on the skin, mucous membranes or cornea. Selection of a suitable surface active agent can thus be based in part on the site being treated. For example, amphoteric or nonionic surface active agents known in the art are selected for uses in and around the eyes to avoid corneal irritation. One skilled in the art can readily select a surface active agent and formulation suitable for a particular site and pruritic condition as well as for other factors. [0024]
  • In another embodiment of the present invention a water-insoluble formulation is provided comprising a biocompatible, water-insoluble organic liquid such as a biocompatible oil or lipid suitable as a carrier for the vitamin D. The carrier must be suitable in the sense of being compatible with the vitamin D and any other ingredients and not deleterious to the patient being treated. Suitable organic liquids include petroleum jelly, corn oil or other vegetable oil, mineral oil, lanolin, fish oil and the like. [0025]
  • The Vitamin D compounds of the present invention can also be formulated into bioavailable suspensions or dispersions such as, for example, hydrosols and hydrogels in which a true emulsion is not formed. The formulation is a mixture of two or more substances forming a dispersed phase which is finely divided and uniformly distributed through a dispersion medium which is usually water. The dispersed phase can be a solid or an oil phase with stabilizers to form a stabilized colloidal system. Suspending or dispersing agents may also be added to the formulation and can include surface active agents capable of stabilizing the suspension or dispersion. The preparation of suspensions and ingredients used in the formation of suspensions are well known in the art and one skilled in the art can readily prepare such suspension. [0026]
  • In addition to the above ingredients, the formulations of this invention may also include one or more additional auxiliary ingredients such as diluents, buffers, or preservatives such as methyl hydroxybenzoate and/or anti-oxidants and the like. Such additional ingredients can also be pharmaceutically-acceptable excipients for modifying or maintaining the pH, osmolarity, viscosity, clarity, color, sterility, stability, rate of dissolution, or odor of the formulation. Similarly, the formulation may contain still other pharmaceutically-acceptable excipients for modifying or maintaining release or absorption or penetration of the site by the vitamin D compound. Moreover, other therapeutic substances can be incorporated into the formulation such as, for example, other antipruritic agents, vitamins, antifungals, antiinflammatory agents, antibiotics, sunscreens and the like. [0027]
  • The topical formulations described herein can be used in treating virtually any pruritic site such as for example on the skin, mucous membranes or cornea. Such treatments include scalp treatment as in shampoos, conditioners and the like, rectal treatment, eye treatment, treatment of nasal membranes, treatment of the ear canal, etc. [0028]
  • The formulations in the present invention are intended for use in treating a wide variety of pruritic conditions in humans as well as in non-human mammals, birds, reptiles, amphibians and fish. Conditions that are intended for treatment by the present invention include but are not limited to chickenpox, shingles, plant toxins such as poison ivy, insect bites, chronic kidney failure, liver diseases such as primary biliary cirrhosis and alcoholic cirrhosis, malabsorption syndromes such as steatorhea, HIV infection, AIDS related eosinophilic pustular folliculitus, psoriasis, atopic dermatitis, photosensitivity disorders, lichen planus, polycythemia vera, Grover's disease, glanuloma annulare, lichen nitidus, prurigo nodularis, macular amyloidosis, urticaria pigmentosa, aquagenic pruritus, pemphigus vulgarus, lupis vulgaris, healing cuts and burns, senile pruritus, hypereosinophilic syndrome, chronic uticaria, pruritic eye conditions, and stress. [0029]
  • Preferred embodiments of the invention are illustrated in the following examples. Other embodiments within the scope of the claims herein will be apparent to one skilled in the art from consideration of the specification or practice of the invention as disclosed herein. It is intended that the specification, together with the examples, be considered exemplary only, with the scope and spirit of the invention being indicated by the claims which follow the examples. [0030]
    • EXAMPLE 1
  • This example illustrates antipruritic effect of vitamin D[0031] 3 in Vita Moist Hand and Nail Cream in the alleviating the pruritus of chickenpox.
  • Having becoming ill with chickenpox, I developed severe pruritus. I applied the commercially available skin cream, Vita Moist Hand and Nail Cream (Avon, N.Y.) hereinafter referenced as Vita Moist Cream and the pruritus was completely and immediately alleviated. The effect of the cream lasted for several hours and when the itching returned, I reapplied the cream with the result that the pruritus was again completely and immediately alleviated. [0032]
  • Vita Moist Cream is sold as a skin moisturizer and carries no indication for use in treating pruritus. Upon reviewing the medical literature, I learned that UVB light was effective in treating pruritic conditions and that, incidentally, UVB light also produces vitamin D[0033] 3, I concluded that vitamin D3 was likely to be the active ingredient in Vita Moist Cream. As commercially available, Vita Moist Cream contains 10 μg/ml vitamin D3 among other ingredients. Ingredients present in Vita Moist Cream are as follows:
    VITA MOIST CREAM
    A Purified Water
    E Glycol Stearate
    E Glycerin
    E Isopropyl Palmitate
    E Dimethicone
    E Myristyl Myristate
    E Peg-40 Stearate
    E Stearyl Alcohol
    E Steareth-2
    E Mineral Oil
    F Methylparaben
    F Imidazolidinyl Urea
    F Triethanolamine
    F Fragrance
    F Carbomer-934
    .02000 Retinyl Palmitate
    .02000 Tocopheryl Acetate
    G Corn Oil
    G Hydrolyzed Animal Keratin
    G Propylene Glycol
    G SD Alcohol 40-B
    .00100 Cholecalciferol
    G Disodium EDTA
    G FD&C Yellow No. 5
    G FD&C Red No. 4
    G EXT D&C Violet No. 2
    • EXAMPLE 2
  • This example illustrates the antipruritic effect of vitamin D[0034] 3 formulated in corn oil for alleviating the pruritus of sunburn.
  • A corn oil solution of vitamin D[0035] 3 was prepared by adding 1 gram of vitamin D3 to 20 ml corn oil with mixing for approximately 1 hour followed by brief heating to approximately 45° C. until dissolved. One ml of this solution was mixed with 47 ml corn oil and 2 ml isopropyl myristate to obtain a final concentration of vitamin D3 of 1000 μg/ml.
  • Subject CS developed a sunburn on the back and experienced severe pruritus. Application of Vita Moist Cream provided some but incomplete relief. An intense pruritus returned and was then dealt by applying 1000 μg/ml in corn oil with the result that the prutitus was immediately and completely alleviated. Approximately an one and one-half hours later, the pruritus returned and was alleviated by multiple applications of Vita Moist Cream, vitamin D[0036] 3 at 1000 μg/ml in corn oil, and constant massaging. The pruritus abated completely about one-half hour after these applications.
    • EXAMPLE 3
  • This example illustrates the antipruritic effect of vitamin D[0037] 3 formulated in water-based emulsions in alleviating the pruritus caused by poison ivy.
  • Water-based emulsion formulations: [0038]
  • Water-based emulsions were prepared using Keri® lotion (Bristol-Meyers Squibb Co., N.Y.) and Eucerin® lotion (Beiersdorf, Inc., Norwalk, Conn.). [0039]
  • Keri® lotion has the following composition as indicated on the container label. [0040]
    • KERI® LOTION
  • Water [0041]
  • Petroleum [0042]
  • Glycerin [0043]
  • Dimethicone [0044]
  • Steareth-2 [0045]
  • Cetyl Alcohol [0046]
  • Benzyl Alcohol [0047]
  • Laureth-23 [0048]
  • Magnesium Alimunim Silicate [0049]
  • Tocopheryl Linoleate [0050]
  • Carbomer [0051]
  • BHT [0052]
  • Sodium Hydroxide [0053]
  • Disodium EDTA [0054]
  • Quaternium-16 [0055]
  • Eucerin® lotion has the following composition as indicated on the container label. [0056]
    • EUCERIN® LOTION
  • Water [0057]
  • Mineral Oil [0058]
  • Isopropyl Myristate [0059]
  • PEG-40 Sorbitan [0060]
  • Peroleate [0061]
  • Glyceryl Lanolate [0062]
  • Sorbitol [0063]
  • Propylene Glycol [0064]
  • Cetyl Palmitate [0065]
  • Magnesium Sulfate [0066]
  • Aluminum Sterate [0067]
  • Lanolin [0068]
  • Alcohol [0069]
  • BHT [0070]
  • Methylchloroisothiazolinone [0071]
  • Methylisothiazolinone [0072]
  • Keri® lotion preparations were made containing various concentrations of vitamin D[0073] 3 by mixing stock solutions as indicated below and heating the mixture at 46-50° C. with occasional stirring. 869 μg/ml: One ml of the 5% solution of vitamin D3 from example 2 was mixed with 2 ml corn oil to obtain 16,666 μg/ml solution. 0.55 ml of this solution was then mixed with ten ml of Keri® lotion. 521 μg/ml: 0.55 ml of vitamin D3 in corn oil at 10,000 μg/ml as described above was added to 10 ml Keri® Lotion. 502 μg/ml: 0.55 ml of the 10,000 solution of was mixed with 10 ml Keri® Lotion and 0.4 ml isopropyl myristate. 52 μg/ml: 0.55 ml of 1,000 μg/ml stock solution, prepared by mixing 1 ml of 5% vitamin D3 stock with 2 ml isopropyl myristate and 47 ml corn oil, was added to 10 ml Keri® Lotion. 10 μg/ml: 0.55 ml of 200 μg/ml stock solution, prepared by mixing 1 ml of 5% vitamin D3 stock with 49 ml corn oil and subsequently diluted 1:5 in corn oil, was added to 0.4 ml isopropyl myristate and 10 ml Keri® Lotion.
  • Eucerin® lotion preparation at 869 μg/ml was made as described above for Keri® lotion. [0074]
  • Vita Moist Cream had the composition as shown in example 1. [0075]
  • As placebo control Care Deeply Hand and Nail Cream (Avon, N.Y.) hereinafter referenced as Care Deeply, has the following composition: [0076]
    • CARE DEEPLY HAND AND NAIL CREAM
  • Purified Water [0077]
  • Glycerin [0078]
  • Cocoa Butter [0079]
  • Cetearyl Alcohol [0080]
  • Isopropyl Myristate [0081]
  • Emulsifying Wax [0082]
  • Ceteareth-20 [0083]
  • Isopropyl Lanolate [0084]
  • Choleth-24 [0085]
  • Glycol Stearate [0086]
  • Methylparaben [0087]
  • Lanolin Oil [0088]
  • Imidazolidinyl Urea [0089]
  • Carbomer-941 [0090]
  • Dimethicone [0091]
  • Magnesium Aluminum Silicate [0092]
  • Triethanolamine [0093]
  • Fragrance [0094]
  • Tetrasodium EDTA [0095]
  • FD&C Yellow No. 5 [0096]
  • FD&C Red No. 4 [0097]
  • FD&C Blue No. 1 [0098]
  • Testing Procedure: Subject MS contracted poison ivy rash and tested the various preparations above. Preparations were evaluated by the subject after application to an area of rash approximately 1-10 square centimeters. Comparisons were made of antipruritic effect by marking on a 100 mm visual analog scale consisting of a plain line with the left end labeled “None” and the right end labeled “Maximal”. The subject was instructed to mark the scale at a point which she felt corresponded to the level of itchiness that she was feeling at the treatment site at the appropriate time. The samples were coded so that the subject was not aware of what a given sample was and she was not told if they were expected to have an effect. She carried out the evaluation unaided, applying the samples in any order she chose except where side-by-side comparisons were made as indicated in the tables. From the marked scale the pruritic score was determined as the number of mm from the left side of the scale to the subject's mark. Thus a higher value indicates a high level or pruritus and a low value indicates a low level to no pruritus. Tables 1a through 1c show the antipruritic effect of water-based emulsion preparations. [0099]
  • Table 1a shows an antipruritic effect of Vita Moist Cream containing vitamin D[0100] 3 at 10 μg/ml compared to the control cream, Care Deeply. The pruritus was completely alleviated one minute after application.
    TABLE 1a
    VITA MOIST (Vitamin D3- 10 μg/ml)*
    Time Care Deeply Vita Moist
    (min) Control (D3 - 10 μg/ml)
    0 81 81 
    1 75 0
    5 74 0
    10  76 0
  • In Table 1b, it is seen that Keri® lotion as a vehicle for vitamin D[0101] 3 also produces a rapid and complete antipruritic effect as was seen in Table 1a for Vita Moist Cream. Also, it is seen that the addition of isopropyl myristate to the formulation did not effect the antipruritic effect of vitamin D3.
    TABLE 1b
    KERI LOTION (containing Vitamin D3)
    Time
    (min) 10 10 10* 10* Mean
    0 80  77  78  80  79 
    1 1 0 0 0 0
    5 0 0 0 0 0
    10  0 0 0 0 0
  • Table 1c shows that concentrations of vitamin D[0102] 3 from 10 through 869 μg/ml are effective in rapidly and effectively relieving pruritus.
    TABLE 1c
    KERI LOTION (with added Isopropyl Myristate)
    Time Vitamin D3 Concentrations
    (min) 0 10** 52 502 521* 869
    0 82 79  77  80  80  82 
    1 66 0 35  0 81  0
    5 47 0 0 0 0 0
    10  25 0 0 0 0 0
  • The formulation of 869 μg/ml vitamin D[0103] 3 in Eucerin® was compared with a Eucerin® control vehicle prepared from Eucerin® with an added amount of corn oil identical to that in the active formulation but containing no vitamin D3. No scores were recorded, however, the subject indicated that the Eucerin®-vitamin D3 preparation stopped the pruritus instantly and completely whereas the control had no antiprutitic effect.
    • EXAMPLE 4
  • This example illustrates the antipruritic effect of vitamin D[0104] 3 formulated in oil-based preparations in alleviating the pruritus caused by poison ivy.
  • A petroleum jelly formulation was prepared as follows. One gram of vitamin D[0105] 3 was dissolved in 20 ml corn oil as described in example 2. One ml of the resultant 5% solution was mixed with 4 ml corn oil to obtain a 10,000 μg/ml solution. Ten ml of petroleum jelly was then mixed with 0.55 ml of the 10,000 μg/ml solution upon heating to 50-55° C. to give a resultant concentration of 521 μg/ml. Placebo control was made by adding 0.55 ml corn oil to 10 ml petroleum jelly.
  • The corn oil formulation was prepared by adding 1 ml of the 5% stock solution of vitamin D[0106] 3 in 2 ml isopropyl myristate and 47 ml corn oil to give a final concentration of 1000 μg/ml.
  • Vitamin A and D Ointment (Schering-Plough, Memphis, Tenn.) contained the label-indicated ingredients of vitamin A at 1856 I.U./g and vitamin D at 270 I.U./g or 6.75 μg/ml in white petrolatum and zinc oxide. [0107]
  • The patient and test procedures were as described in example 3. The results of tests using oil-based formulations are in tables 2a through 2c. [0108]
  • In Table 2a it is seen that corn oil as a vehicle for vitamin D[0109] 3 at 1000 μg/ml produced no detectable antipruritic effect when the mean of two tests were compared to vehicle control. In contrast, Table 2b showed an antipruritic effect for vitamin D3 at a concentration of 521 μg/ml in the vehicle, petroleum jelly. The commercial product, A and D ointment shown in Table 2c showed no antipruritic effect.
    TABLE 2a
    CORN OIL
    Vitamin D3
    Time Control (1000 μg/ml)
    (min) 1 2 Mean 1 2 Mean
    0 82 82 82 80 81 81
    1 81 48 65 80 81 81
    5 81 12 47 81 58 70
    10  83  2 43 60 58 59
  • [0110]
    TABLE 2b
    PETROLEUM JELLY
    Time Vitamin D3
    (min) Control (521 μg/ml)
    0 80 72
    1 79 11
    5 78 10
    10  58  9
  • [0111]
    TABLE 2c
    A AND D OINTMENT*
    A and D
    Petroleum Ointment
    Time Jelly (D3-6.75 μg/ml)
    (min) 1 2 Mean 1 2 Mean
    0 81 68 75 81 58 70
    1 81 2 42 1 61 31
    5 0 0 0 80 61 71
    10  0 43 22 82 52 67
    • EXAMPLE 5
  • This example illustrates the antipruritic effect of vitamin D[0112] 3 formulated in a water-based suspension in alleviating the pruritus caused by poison ivy.
  • Vita Moist Cream was used as control reference formulation and this had the composition as shown in example 1. Vita Moist Body Lotion (Avon, N.Y.), is a commercially available aqueous suspension formulation containing vitamin D[0113] 3. This composition contains the following ingredients.
    VITA MOIST BODY LOTION
    A Purified Water
    E Stearic Acid
    E Hydrogenated Soybean Oil
    E Glycerin
    E Squalane
    F Cetyl Acetate
    F Triethanolamine
    F Glyceryl Stearate
    F Sesame Oil
    F Methylparaben
    F Magnesium Aluminum Silicate
    F Fragrance
    F Propylparaben
    F Acetylated Lanolin Alcohol
    .05000 Tocopheryl Acetate
    .02500 Retinyl Palmitate
    F Corn Oil
    F BHT
    F Propylene Glycol
    F SD Alcohol 40-B
    .00125 Cholecalciferol
    F BHA
    F Disodium EDTA
    F FD&C Yellow No. 5
    F FD&C Red No. 4
    F EXT D&C Violet No. 2
  • The patient and test procedures were as described in example 3. The results of tests using oil-based formulations are in Table 3. [0114]
    TABLE 3
    VITAMIN D3 SUSPENSION (VITA MOIST LOTION)
    Vita Moist Cream Vita Moist Lotion
    Time (D3 - 10 μg/ml) (D3 - 12.5 μg/ml)
    (min) 1 2 Mean 1 2 Mean
    0 70  79  74  71  78 74
    1 0 78  39  49  78 64
    5 0 0 0 11  56 34
    10  0 0 0 3  5  4
  • As reported in example 3, Vita Moist Cream again completely alleviated the pruritus, although in this test, complete effectiveness was seen at the 5 minute observation rather than at the 1 minute observation in example 3. In comparison to this, Vita Moist Lotion only partially alleviation of the pruritis at 5 minutes and nearly complete relief was obtained by 10 minutes. Thus the suspension preparation appeared to be less rapid in producing the antipruritic effect than was the emulsion preparation, Vita Moist Cream. [0115]
    • EXAMPLE 6
  • This example illustrates the dose-response relationship of Vitamin D[0116] 3 in a water-based emulsion vehicle prepared by mixing Vita Moist Cream containing Vitamin D3 with Care Deeply Cream which contains no Vitamin D3.
  • Serial dilutions of Vita Moist Cream were made from an initial 5 ml quantity of Vita Moist Cream by adding successive 5 ml quantities of the diluent, Care Deeply Cream, to the starting formulation and subsequent 5 ml aliquots of successive dilutions as follows: [0117]
  • 1.5 ml Vita Moist+5 ml diluent - - - 5.0 μg/ml [0118]
  • 2.5 ml of 5 μg/ml+5 ml diluent - - - 2.5 μg/ml [0119]
  • 3.5 ml of 2.5 μg/ml+5 ml diluent-1.25 μg/ml [0120]
  • 4. 5 ml of 1.2 μg/ml+5 ml diluent-0.5 μg/ml [0121]
  • 5.5 ml of 0.5 μg/ml+5 ml diluent-0.25 μg/ml [0122]
  • 6. 5 ml diluent [0123]
  • After coding with numbers 1-6 as above, the preparations were randomly sorted and again coded A-E and tested two at a time in alphabetical order. The results are shown in the figure. As can be seen concentrations of 2.5 and 5 μg/ml produced rapid and complete alleviation of pruritus. The concentrations of 1.25 μg/ml and 0.5 μg/ml produced some antipruritic effect but the effect was not complete nor was it rapid and sustained. The minimal effective concentration in this formulation appears to be between 1.25 and 2.5 μg/ml. [0124]
    • EXAMPLE 7
  • The following example illustrates the clinical testing of vitamin D formulations in patients having uremic pruritus. [0125]
  • In this study, vitamin D formulations will be tested against placebo. The vitamin D preparations will be based upon the formulations discussed above. The placebo will contain only the formulation without vitamin D. [0126]
  • The study would be double blind, meaning that both the nurse and the patient will be unaware of which cream contains the test material and which contains only placebo. The containers will be coded so that only the attending physician will know which is which. The code may be different from one formulation set to the next. [0127]
  • The nurse protecol is as follows: [0128]
  • The patient must be suffering from chronic kidney failure and be experiencing bothersome itchiness at the time of the office visit. The patient will be asked if they would like to volunteer to try this new treatment. It will be explained that this is a trial of a cream that relieves itchiness in chickenpox and poison ivy and that it may or may not help them. [0129]
  • The patient will be assisted in understanding and completing the questionnaire. If needed, the nurse can assist by writing the answers given by the patient. The questionnaire is as follows: [0130]
    Cream Number — —
     1. Patient's name and phone number.
     2. Date and time.
     3. Age/Sex.
     4. Date when dialysis was started.
     5. What kind of renal disease do you have?
     6. Do you have a history of persistent itchiness?
    If so, for how long?
     7. Is your itchiness constant or does it come and
    go? If it's not constant, when is it usually
    the worst?
     8. Are you itching right now?
     9. Do you have itchiness all over your body or
    only on part of your body? If only on part of
    your body, please indicate where.
    10. What treatments have you tried to reduce the
    itchiness and which have been the most
    effective?
    Nurses' comments (to be filled out after evaluation):
    Follow up comments:
    Nurses' signature
    Doctors' signature
  • Chose the sites to apply the creams based on where the itching is most severe. Apply creams “X” and “O” to areas of roughly equal size and itchiness. Indicate under “Nurses' comments” where the creams were applied. If the itching is general, use one forearm for the test cream and the other forearm for the placebo cream. The cream should soak in completely. If it doesn't, you put too much on. If the patient has an adverse reaction to the cream, stop the trial and remove the cream immediately. [0131]
  • If one of the creams relieves the itching, let them apply the cream to all of the affected areas of skin after the trial is completed before leaving the office. Ask the patient to make a note of when the itchiness returns and explain that you will make a follow up call to ask how long the treatment lasted. Do not give any extra to take home. Explain that the attending physician is barred by law to prescribe or dispense it. [0132]
  • Please indicate under “Nurses' comments” if there is anything about the patient that you think we should know when reviewing the questionnaire. This could include problems other than uremia that could cause pruritus. [0133]
  • Treatment is evaluated by the patient as discussed in Example 3 above. The patient is instructed as to how to mark the 100 mm visual scale from “None” to “Maximal” pruritus. The scale is explained with no suggestion as to where the mark should be placed. Only the patient will decide where to place the mark. [0134]
    Patient's name and date:
    TREATMENT EVALUATION
    Please indicate how serious the itchiness is using the following scales.
    make a mark on the line at the point that you feel corresponds to the
    severity of the itchiness that you are experiencing at the treatment sites
    for each appropriate time. Slight itchiness would be indicated by making a
    mark near the left side of the scale while severe itchiness would be
    indicated by making a mark near the right side of the scale. Maximal
    itchiness means the most severe itchiness that you can imagine.
    BEFORE APPLICATION
    Site X NONE MAXIMAL
    Site O NONE MAXIMAL
    ONE MINUTE AFTER APPLICATION
    Site X NONE MAXIMAL
    Site O NONE MAXIMAL
    FIVE MINUTES AFTER APPLICATION
    Site X NONE MAXIMAL
    Site O NONE MAXIMAL
    TEN MINUTES AFTER APPLICATION
    Site X NONE MAXIMAL
    Site O NONE MAXIMAL
    Please describe in your own words the effect of the cream on the itchiness.
    If this treatment is effective, we will call you for a follow up assessment to
    find out how long the treatment is effective. Please try to note when the
    itchiness returns.
    Thank you very much!
  • Approximately 10 patients will be used in the study and each patient will receive both vitamin D treatment formulation and placebo. Data will be collected and statistical comparison will be made between effects of the formulation and effects of placebo. [0135]
  • In view of the above, it will be seen that the several advantages of the invention are achieved and other advantageous results attained. [0136]
  • As various changes could be made in the above methods and compositions without departing from the scope of the invention, it is intended that all matter contained in the above description and shown in the accompanying drawings shall be interpreted as illustrative and not in a limiting sense. [0137]

Claims (20)

What is claimed is:
1. A method for treating pruritus comprising topically administering vitamin D or an analog thereof in a therapeutically effective formulation which is pharmaceutically acceptable for topical application.
2. The method according to
claim 1
 wherein the therapeutically effective formulation is an emulsion comprising water, a water-insoluble organic liquid, a surface active agent, and vitamin D or an analog thereof.
3. The method according to
claim 2
 wherein the vitamin D comprises a compound selected from the group consisting of alacalcidol, calcifediol, calcitriol, cholecalciferol, dihydrotachysterol and ergocalciferol.
4. The method according to
claim 2
 wherein the analog of vitamin D comprises a vitamin D compound having side-chain modifications of introduction of unsaturation; transposing, adding, removing or substituting hydroxyl groups; substituting hydrogens; forming carbocyclic structure; introducing a heteroatom link; inverting stereochemically; removing or adding alkyl groups; or changing the number of links in the side chain.
5. The method according to
claim 2
 wherein the surface active agent is selected from the group consisting of PEG-40 stearate, steareth-2, PEG-40 sorbitan peroleate, laureth-23 and combinations thereof.
6. The method according to
claim 5
 wherein the therapeutically effective formulation comprises at least about 50% water, from about 1 to about 5% PEG-40 stearate, from 1 to about 5% steareth-2 and cholecalciferol at a concentration of about 10 μg/ml.
7. The method according to
claim 6
 wherein the therapeutically effective formulation comprises cholecalciferol at a concentration of at least about about 2.5 μg/ml.
8. The method according to
claim 7
 wherein the pruritus results from a condition selected from the group consisting of chickenpox, shingles, plant toxins such as poison ivy, insect bites, chronic kidney failure, liver diseases such as primary biliary cirrhosis and alcoholic cirrhosis, malabsorption syndromes such as steatorhea, HIV infection, AIDS related eosinophilic pustular folliculitus, psoriasis, atopic dermatitis, photosensitivity disorders, lichen planus, polycythemia vera, Grover's disease, glanuloma annulare, lichen nitidus, prurigo nodularis, macular amyloidosis, urticaria pigmentosa, aquagenic pruritus, pemphigus vulgarus, lupis vulgaris, healing cuts and burns, senile pruritus, hypereosinophilic syndrome, chronic uticaria, pruritic eye conditions, stress, and combinations thereof.
9. The method according to
claim 1
 wherein the therapeutically effective formulation comprises vitamin D or analog thereof and a water insoluble organic liquid.
10. The method according to
claim 9
 wherein the vitamin D comprises a compound selected from the group consisting of alacalcidol, calcifediol, calcitriol, cholecalciferol, dihydrotachysterol and ergocalciferol.
11. The method according to
claim 9
 wherein the analog of vitamin D comprises a vitamin D compound having side-chain modifications of introduction of unsaturation; transposing, adding, removing or substituting hydroxyl groups; substituting hydrogens; forming carbocyclic structure; introducing a heteroatom link; inverting stereochemically; removing or adding alkyl groups; or changing the number of links in the side chain.
12. The method according to
claim 10
 wherein the water-insoluble organic liquid is selected from the group consisting of corn oil, petroleum jelly and fish oil.
13. The method according to
claim 12
 wherein the therapeutically effective formulation contains at least about 521 μg cholecalciferol per ml.
14. The method according to
claim 13
 wherein the pruritus results from a condition selected from the group consisting of chickenpox, shingles, plant toxins such as poison ivy, insect bites, chronic kidney failure, liver diseases such as primary biliary cirrhosis and alcoholic cirrhosis, malabsorption syndromes such as steatorhea, HIV infection, AIDS related eosinophilic pustular folliculitus, psoriasis, atopic dermatitis, photosensitivity disorders, lichen planus, polycythemia vera, Grover's disease, glanuloma annulare, lichen nitidus, prurigo nodularis, macular amyloidosis, urticaria pigmentosa, aquagenic pruritus, pemphigus vulgarus, lupis vulgaris, healing cuts and burns, senile pruritus, hypereosinophilic syndrome, chronic uticaria, pruritic eye conditions, stress, and combinations thereof.
15. The method according to
claim 1
 wherein the therapeutically effective formulation is a suspension comprising water and a dispersed phase containing vitamin D or analog thereof.
16. The method according to
claim 15
 wherein the vitamin D comprises a compound selected from the group consisting of alacalcidol, calcifediol, calcitriol, cholecalciferol, dihydrotachysterol and ergocalciferol.
17. The method according to
claim 15
 wherein the analog of vitamin D comprises a vitamin D compound having side-chain modifications of introduction of unsaturation; transposing, adding, removing or substituting hydroxyl groups; substituting hydrogens; forming carbocyclic structure; introducing a heteroatom link; inverting stereochemically; removing or adding alkyl groups; or changing the number of links in the side chain.
18. The method according to
claim 16
 wherein the dispersed phase comprises stearic acid and hydrogenated soybean oil and squalene.
19. The method according to
claim 18
 wherein the therapeutically effective formulation contains at least about 10 μg cholcalciferol per ml.
20. The method according to
claim 19
 wherein the pruritus results from a condition selected from the group consisting of chickenpox, shingles, plant toxins such as poison ivy, insect bites, chronic kidney failure, liver diseases such as primary biliary cirrhosis and alcoholic cirrhosis, malabsorption syndromes such as steatorhea, HIV infection, AIDS related eosinophilic pustular folliculitus, psoriasis, atopic dermatitis, photosensitivity disorders, lichen planus, polycythemia vera, Grover's disease, glanuloma annulare, lichen nitidus, prurigo nodularis, macular amyloidosis, urticaria pigmentosa, aquagenic pruritus, pemphigus vulgarus, lupis vulgaris, healing cuts and burns, senile pruritus, hypereosinophilic syndrome, chronic uticaria, pruritic eye conditions, stress, and combinations thereof.
US09/123,885 1995-10-10 1998-07-28 Treatment of pruritus with vitamin d and analogs thereof Abandoned US20010007866A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/123,885 US20010007866A1 (en) 1995-10-10 1998-07-28 Treatment of pruritus with vitamin d and analogs thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US503095P 1995-10-10 1995-10-10
US08/720,698 US5789399A (en) 1995-10-10 1996-10-02 Treatment of pruritus with vitamin D and analogs thereof
US09/123,885 US20010007866A1 (en) 1995-10-10 1998-07-28 Treatment of pruritus with vitamin d and analogs thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/720,698 Division US5789399A (en) 1995-10-10 1996-10-02 Treatment of pruritus with vitamin D and analogs thereof

Publications (1)

Publication Number Publication Date
US20010007866A1 true US20010007866A1 (en) 2001-07-12

Family

ID=21713776

Family Applications (2)

Application Number Title Priority Date Filing Date
US08/720,698 Expired - Lifetime US5789399A (en) 1995-10-10 1996-10-02 Treatment of pruritus with vitamin D and analogs thereof
US09/123,885 Abandoned US20010007866A1 (en) 1995-10-10 1998-07-28 Treatment of pruritus with vitamin d and analogs thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US08/720,698 Expired - Lifetime US5789399A (en) 1995-10-10 1996-10-02 Treatment of pruritus with vitamin D and analogs thereof

Country Status (5)

Country Link
US (2) US5789399A (en)
EP (1) EP0897300A4 (en)
JP (1) JPH11514999A (en)
AU (1) AU7364896A (en)
WO (1) WO1997013518A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060292080A1 (en) * 1998-09-11 2006-12-28 Connetics Australia Pty Ltd Vitamin formulation
US20100081637A1 (en) * 2008-10-01 2010-04-01 Innovia Skincare Corp. Eczema treatment with vitamin D and analogs thereof method, composition and cream
US20110014135A1 (en) * 2005-06-01 2011-01-20 Stiefel Research Australia Pty Ltd Vitamin formulation

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225431B1 (en) * 1991-07-05 2001-05-01 Biocompatibles Limited Biocompatibilizing process
US6284854B1 (en) * 1991-07-05 2001-09-04 Biccompatibles Limited Polymeric surface coatings
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
US6242434B1 (en) * 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6566353B2 (en) * 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US20030129194A1 (en) * 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
ZA991856B (en) 1998-08-27 1999-09-22 Henkel Corp Storage-stable compositions useful for the production of structural foams.
PT1178808E (en) * 1999-04-23 2012-08-16 Leo Pharma As Non-aqueous pharmaceutical composition for dermal use to treat psoriasis comprising a vitamin d, a corticosteroid and a solvent component
US6423746B1 (en) * 1999-07-03 2002-07-23 The William M. Yarbrough Foundation Urushiol induced contact dermatitis and method of use
US6117904A (en) * 1999-09-03 2000-09-12 Murphy; Donald M. Treatment of pruritus
US6541517B1 (en) 1999-09-03 2003-04-01 Donald M. Murphy Treatment of skin disorders
US20090098065A1 (en) * 2000-01-11 2009-04-16 Avikam Harel Composition and methods for the treatment of skin disorders
WO2002006218A2 (en) * 2000-07-18 2002-01-24 Bone Care International, Inc. STABILIZED 1α-HYDROXY VITAMIN D
AU2002241738A1 (en) * 2000-12-29 2002-07-16 The Trustees Of Columbia University In The City Of New York Use of iv emulsions with different triglyceride composition, particle size and apolipoprotein e for targeted tissue delivery of hydrophobic compounds
US20030018095A1 (en) * 2001-04-27 2003-01-23 Agarwal Rajat K. Thermosettable compositions useful for producing structural adhesive foams
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
US20080020025A1 (en) * 2003-08-28 2008-01-24 Pharmaionx, Inc. Composition for wound care and method of using same
WO2005115403A2 (en) * 2004-05-26 2005-12-08 Cedars-Sinai Medical Center Induction of innate immunity by vitamin d3 and its analogs
US20060073107A1 (en) * 2004-10-04 2006-04-06 Person John R Use of vitamin D3 (cholecalciferol) in sunscreens
US20060172951A1 (en) * 2005-01-28 2006-08-03 Dantzig Paul I Age related macular degeneration and cutaneous signs of mercury toxicity
BRPI0609630A2 (en) * 2005-05-10 2010-04-20 Dermipsor Ltd compositions and methods for treating hyperproliferative epidermal diseases
FR2893847B1 (en) * 2005-11-30 2010-10-29 Galderma Sa SPRAY COMPOSITION COMPRISING VITAMIN D DERIVATIVE AND OILY PHASE
US20070203040A1 (en) * 2006-02-24 2007-08-30 Harry Reicherz Bar soap
BRPI0715636A2 (en) * 2006-08-29 2013-07-02 Teva Pharma stable pharmacologically active compositions including low ph compatibility vitamin D and corticosteroid-containing compounds
TWI433674B (en) 2006-12-28 2014-04-11 Infinity Discovery Inc Cyclopamine analogs
US20090017129A1 (en) * 2007-07-13 2009-01-15 Ma Or Ze Ev Dead Sea minerals enriched anti-inflammatory pharmaceutical composition for treatment of cutaneous dryness, itching, peeling and tightness, especially in hemodialysis patients and preparation and treatment methods thereof
AU2009337184A1 (en) * 2009-01-16 2011-07-28 Anzamed International Limited Medicament for the treatment of pain and inflammation
ES2567134T3 (en) 2009-08-05 2016-04-20 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
US9394313B2 (en) 2010-09-14 2016-07-19 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
CA2877102C (en) * 2011-06-29 2020-06-30 Avidas Pharmaceuticals Llc Topical formulations including lipid microcapsule delivery vehicles and their uses
JP6796638B2 (en) 2015-06-04 2020-12-09 ペレファーム, インク.Pellepharm, Inc. Topical formulations and their use for the delivery of hedgehog inhibitory compounds
US20170231968A1 (en) * 2016-02-11 2017-08-17 PellePharm, Inc. Method for relief of and treatment of pruritus

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3711602A (en) * 1970-10-30 1973-01-16 Crown Zellerbach Corp Compositions for topical application for enhancing tissue penetration of physiologically active agents with dmso
US4416886A (en) * 1981-07-29 1983-11-22 Dermall Limited Method of treating pruritis and composition therefor
US4997824A (en) * 1987-07-22 1991-03-05 Teva Pharmaceutical Industries Ltd. Combination of cholecalciferol derivatives for the treatment of renal bone disease
GB8915770D0 (en) * 1989-07-10 1989-08-31 Leo Pharm Prod Ltd Chemical compounds
US5057500A (en) * 1990-02-12 1991-10-15 Dermatologic Research Corporation Treatment of pruritis with esters and amides
US5362719A (en) * 1990-03-01 1994-11-08 Leo Pharmaceutical Products, Ltd. A/S Lovens Kemiske Fabrik Produktionsaktieselskab) Use of vitamin-D analogues in the treatment of acne
GB9007236D0 (en) * 1990-03-30 1990-05-30 Leo Pharm Prod Ltd Chemical compounds
TW267161B (en) * 1992-11-20 1996-01-01 Hoffmann La Roche

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060292080A1 (en) * 1998-09-11 2006-12-28 Connetics Australia Pty Ltd Vitamin formulation
US8263580B2 (en) 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
US20110014135A1 (en) * 2005-06-01 2011-01-20 Stiefel Research Australia Pty Ltd Vitamin formulation
US8298515B2 (en) 2005-06-01 2012-10-30 Stiefel Research Australia Pty Ltd. Vitamin formulation
US8629128B2 (en) 2005-06-01 2014-01-14 Stiefel West Coast, Llc Vitamin formulation
US20100081637A1 (en) * 2008-10-01 2010-04-01 Innovia Skincare Corp. Eczema treatment with vitamin D and analogs thereof method, composition and cream
WO2011041075A1 (en) * 2009-09-30 2011-04-07 Innovia Skincare Corp. Eczema treatment with vitamin d and analogs thereof method, composition and cream

Also Published As

Publication number Publication date
WO1997013518A1 (en) 1997-04-17
EP0897300A1 (en) 1999-02-24
EP0897300A4 (en) 2000-07-05
JPH11514999A (en) 1999-12-21
US5789399A (en) 1998-08-04
AU7364896A (en) 1997-04-30

Similar Documents

Publication Publication Date Title
US5789399A (en) Treatment of pruritus with vitamin D and analogs thereof
US11331326B2 (en) Composition for prevention or treatment of inflammatory skin diseases or severe pruritus comprising the aqueous solubilized ursodeoxycholic acid
DE69926843T2 (en) ACTIVE VITAMIN D3 CONTAINING LOTIONS IN THE FORM OF EMULSIONS
US7368122B1 (en) Skin cream
CA2180454A1 (en) External preparation for skin protection
BRPI0616520A2 (en) oil-in-water emulsion, process for preparing an emulsion and its use
CA2001797A1 (en) Topical ointment for dermatosis
JP4398641B2 (en) Hypoallergenic and non-irritating skin care preparations
HU218921B (en) Topical use of anorganic salt of stroncium (ii) for producing pharmaceutical compositions for treating neurogen skin-diseases
US20100081637A1 (en) Eczema treatment with vitamin D and analogs thereof method, composition and cream
US7604812B2 (en) Hypoallergenic and non-irritant skin care formulations
AU2002234581A1 (en) Hypoallergenic and non-irritant skin care formulations
DE60035613T2 (en) Topical, cosmetic and pharmaceutical compositions containing specific alkoxylated diesters of fumaric acid
US6117904A (en) Treatment of pruritus
EP1594456B1 (en) Use of a composition comprising vitamin k1 oxide or a derivative thereof for the treatment and/or the prevention of mammal dermatological lesions
EP3458042A1 (en) Carboxylic acids for treating/preventing a skin disease
RU2426540C1 (en) Anti-inflammatory and anti-allergic medication and based on it pharmaceutical composition
AU2016348527A1 (en) Methods of treatment of acne vulgaris using topical dapsone compositions
JPH06100451A (en) Skin external agent
Meckfessel et al. 21. A Novel, 100% Mineral Liquid Facial Sunscreen SPF 50 is Significantly Preferred to a 100% Mineral Facial Lotion SPF 50
Stankier Diseases of the skin. Psoriasis.

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION